Write your message
Volume 3, Issue 4 (Fall 2018)                   jogcr 2018, 3(4): 169-171 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Faghih N, Arab M. A Case Report of Complete and Prolonged Response to Hormonal Therapy in Recurrent Metastatic Endometrial Cancer. jogcr. 2018; 3 (4) :169-171
URL: http://jogcr.com/article-1-216-en.html
1- Gyneco-oncology Fellowship Assistant, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2- Professor of Gyneco-oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran , drmarab@sbmu.ac.ir
Abstract:   (146 Views)

Background & Objective: Endometrial cancer is one of the most common gynecologic malignancies in developed countries. Survival rate in metastatic endometrial adenocarcinoma recurrence is reduced, and treatment in these patients is mostly palliative.  One of the therapeutic options in the endometrial adenocarcinoma recurrence is hormone therapy. The expected response to the hormonal treatment is about 10-20%.
Case Report: This is a case report from 57-year-old woman suffering from stage IA - Grade 1 endometrial cancer, who had vaginal carcinoma recurrence with liver and pulmonary metastasis 5.5 years after the initial treatment. Due to positive hormone receptor and the pathological profile of the tumor, hormone therapy with tamoxifen and megestrol was started. The treatment evaluation revealed complete response within five months with clearance of lung and liver metastatic lesions. There is no evidence of disease and metastases in the patient's examination and imaging after 3 years of starting hormone therapy.
Conclusion: In the case of well-differentiated recurrent and metastatic endometrial cancer, good response to the hormone therapy by the least complications might be achieved.

Full-Text [PDF 206 kb]   (38 Downloads) |   |   Full-Text (HTML)  (10 Views)  

✅ In the case of well-differentiated recurrent and metastatic endometrial cancer, good response to the hormone therapy by the least complications might be achieved.


Systematic Review: Case Report | Subject: Gynecology Oncology
Received: 2018/05/8 | Accepted: 2019/06/3 | Published: 2018/09/16

References
1. Campose SM, Cohn DE. Treatment of recurrent or metastatic endometrial cancer. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com (Accessed on 11 Jul, 2018.)
2. Pectasides D, Pectasides E, Economopoulos T. Systemic therapy in metastatic or recurrent endometrial cancer. J Cancer Treat Rev. 2007;33(2):177-90. [DOI:10.1016/j.ctrv.2006.10.007] [PMID] [DOI:10.1016/j.ctrv.2006.10.007] [PMID]
3. Plaxe S. Endometrial carcinoma: Pretreatment evaluation, staging, and surgical treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com (Accessed on 11 Feb, 2014.)
4. Chen L, Berek JS. Endometrial carcinoma: Epidemiology and risk factors. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com (Accessed on 8 Feb, 2017.)
5. Markman NJ EJoC. Hormonal therapy of endometrial cancer. J Eur J Cancer. 2005;41(5):673-5. [DOI:10.1016/j.ejca.2004.12.008] [PMID] [DOI:10.1016/j.ejca.2004.12.008] [PMID]
6. Duska L. Overview of approach to endometrial cancer survivors. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com (Accessed on 28 Aug, 2017.)
7. Rendina G, Donadio C, Fabri Me-a, Mazzoni P, Nazzicone P. Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma. J Eur J Obstet Gynecol Reprod Biol. 1984;17(4):285-91. [DOI:10.1016/0028-2243(84)90071-6] [DOI:10.1016/0028-2243(84)90071-6]
8. Rauh-Hain JA, del Carmen MG. Treatment for advanced and recurrent endometrial carcinoma: combined modalities. The Oncologist. 2010;15(8):852-61. [DOI:10.1634/theoncologist.2010-0091] [PMID] [PMCID] [DOI:10.1634/theoncologist.2010-0091] [PMID] [PMCID]
9. Crespo C, González-Martı́n A, Lastra E, Garcı́a-López J, Moyano AJGo. Metastatic endometrial cancer in lung and liver: complete and prolonged response to hormonal therapy with progestins. J Gynecol Oncol. 1999;72(2):250-5. [DOI:10.1006/gyno.1998.5229] [PMID] [DOI:10.1006/gyno.1998.5229] [PMID]
10. Whitney CW, Brunetto VL, Zaino RJ, Lentz SS, Sorosky J, Armstrong DK, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Gynecol Oncol. 2004;92(1):4-9. [DOI:10.1016/j.ygyno.2003.09.018] [PMID] [DOI:10.1016/j.ygyno.2003.09.018] [PMID]
11. Fiorica JV, Brunetto VL, Hanjani P, Lentz SS, Mannel R, Andersen W. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Gynecol Oncol. 2004;92(1):10-4. [DOI:10.1016/j.ygyno.2003.11.008] [PMID] [DOI:10.1016/j.ygyno.2003.11.008] [PMID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


© 2019 All Rights Reserved | Journal of Obstetrics, Gynecology and Cancer Research (JOGCR)

Designed & Developed by : Yektaweb | Piblisher: Farname Inc.